Identification of gefitinib off-targets using a structure-based systems biology approach; their validation with reverse docking and retrospective data mining | Scientific Reports
IRESSA (gefitinib) for Metastatic EGFR Mutation-Positive NSCLC - Cancer Therapy Advisor